 | • レポートコード：MRC2303I0056 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の避妊薬（ピル）市場規模が、予測期間中に年平均9%で成長すると予測しています。本レポートは、避妊薬（ピル）の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、ホルモン種類別（プロゲスチン錠剤、配合剤、その他）分析、カテゴリ別（ジェネリック、ブランド）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Bayer AG、Amneal Pharmaceuticals LLC、Teva Pharmaceuticals、Abbvie Inc. (Allergan PLC)、Pfizer Inc.、Johnson & Johnson、Aurobindo Pharma Limited、Organon International (Merck & Co. Inc.) 、Sanofi SA、Mayne Pharmaなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の避妊薬（ピル）市場規模：ホルモン種類別 - プロゲスチン錠剤の市場規模 - 配合剤の市場規模 - その他ホルモン種類の市場規模 ・世界の避妊薬（ピル）市場規模：カテゴリ別 - ジェネリック避妊薬（ピル）の市場規模 - ブランド避妊薬（ピル）の市場規模 ・世界の避妊薬（ピル）市場規模：地域別 - 北米の避妊薬（ピル）市場規模 アメリカの避妊薬（ピル）市場規模 カナダの避妊薬（ピル）市場規模 メキシコの避妊薬（ピル）市場規模 … - ヨーロッパの避妊薬（ピル）市場規模 ドイツの避妊薬（ピル）市場規模 イギリスの避妊薬（ピル）市場規模 フランスの避妊薬（ピル）市場規模 … - アジア太平洋の避妊薬（ピル）市場規模 中国の避妊薬（ピル）市場規模 日本の避妊薬（ピル）市場規模 インドの避妊薬（ピル）市場規模 … - 中東/南米の避妊薬（ピル）市場規模 南アフリカの避妊薬（ピル）市場規模 ブラジルの避妊薬（ピル）市場規模 アルゼンチンの避妊薬（ピル）市場規模 … - その他地域の避妊薬（ピル）市場規模 ・競争状況 ・市場機会・将来の動向 |
The contraceptive pills market is poised to register a CAGR of 9% during the forecast period.
The COVID-19 pandemic had a substantial impact on the contraceptive pills market. Several guidelines are being introduced about contraceptive pills that have benefitted the market during the COVID-19 pandemic. For instance, according to the guidelines by MoHFW published in October 2021 by the government of India, oral contraceptive pills should be freely available in all public health facilities (including the COVID care facilities). According to the same source, extra packets (at least two months’ supply) of oral contraceptive pills can be handed over to repeat clients to avoid multiple contacts. Thus, the demand for contraceptive pills remained significant during the pandemic.
However, with the introduction of vaccines, government authorities and healthcare organizations have recommended reducing the consumption of contraceptive pills before administering vaccines. For instance, according to an April 2021 update by the Taiwan Centers for Disease Control, the Advisory Committee on Immunization Practices (ACIP), the ACIP made a resolution to add related reminding messages on the notice of “precautions to take before COVID-19 vaccination with AstraZeneca vaccine.” Taking contraceptive pills and undergoing hormone therapy are risk factors for blood clotting, thus, people receiving these treatments are advised to pause the process at least 28 days before and after inoculation at this stage. Hence, the COVID-19 pandemic had a significant impact on the market initially. However, as the pandemic subsided, the market is expected to have a stable growth during the forecast period.
Furthermore, the increasing rate of unintended pregnancies is a major factor driving the demand for contraceptive pills, thereby contributing to the market growth. For instance, according to a March 2021 update by the United Nations Populations Fund, the number of unintended pregnancies was 1.4 million across 115 low- and middle-income countries. Thus, such statistics indicate the increasing demand for contraceptive pills across the globe, thereby contributing to the market growth.
Additonally, various initiatives taken by governments worldwide is also expected to boost the market growth. For instance, according to the Council of Ministers of Spain in May 2022, the Spainish government reformed the law regarding sexual and reproductive health and the voluntary interruption of pregnancy. New measures on sexuality education and contraception, menstrual health, pregnancy, childbirth, abortion, and reproductive violence was taken. It was also mentioned that the morning-after contraceptive pill will be made available free of charge in health centres and future public centres specialising in sexual and reproductive rights, and must be available in all pharmacies.
Moreover, several developments by key market players are expected to further boost the market growth. For instance, in April 2021, Mayne Pharma reported that the US FDA had approved NEXTSTELLIS (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) for the prevention of pregnancy. NEXTSTELLIS is the first and only contraceptive pill containing E4, a naturally occurring estrogen, now produced from a plant source, with a unique mechanism of action that offers potential advantages over other estrogens.
Therefore, owing to the abovementioned factors, the market studied is anticipated to witness growth over the forecast period. However, side effects associated with the use of contraceptive drugs and increased usage of alternative birth control methods are the factors expected to hinder market growth over the forecast period.
Contraceptive Pills Market Trends
The Generic Segment is Expected to Hold a Significant Share of the Market Over the Forecast Period
By category, the generic segment is expected to witness significant growth. The generic segment has the largest share in the market due to the widespread adoption of generic contraceptives, owing to their low prices and market availability. For instance, in February 2022, Asda lowered the price of its generic emergency hormonal contraception (EHC) pill to GBP 9.89 (USD 13.33) to ensure it is more accessible to women in the United Kingdom.
Furthermore, the increasing need for population control and the rising incidence of abortion has driven the growth of generic contraceptive pills in the market. Thus, several market players are engaged in implementing strategic initiatives, thereby boosting market growth. For instance, in March 2021, Mayne Pharma Group Limited commercially launched a generic version of ORTHO-CEPT (desogestrel and Ethinyl estradiol 0.15 mg/0.03 mg) tablets to customers in the United States. Such developments are likely to positively impact the adoption of generic contraceptive pills among women.
Hence, due to the abovementioned factors, the segment is expected to witness significant growth during the forecast period.
North America is Expected to Hold the Largest Share in the Market
Within North America, the US holds a major share of the market owing to rapid developments in the healthcare infrastructure and high awareness about contraceptive pills in the region. For instance, according to the data published by NCBI in September 2022, the birth control contraception pill is the most commonly prescribed form of contraception in the United States, and approximately 25% of women aged 15 to 44 who currently use contraception reported using the pill as their method of choice; the most commonly prescribed pill was found to be the combined hormonal pill with estrogen and progesterone. Thus, the consumption of contraceptive pills in the United States is significant and is expected to continue over the forecast period.
Several organizations are also engaged in implementing strategic initiatives in the country. For instance, as per the Bill & Melinda Gates Foundation data published in 2022, the foundation is aiming to offer USD 280 million per year from 2021 to 2030 for developing new and improved contraceptive technologies, support family planning programs that reflect the preferences of local communities, and enable women and girls to be in control of their contraceptive care. Such developments are anticipated to boost the adoption of oral contraceptive pills in the country, thereby boosting the market growth.
Hence, due to the abovementioned factors, the market is expected to witness significant growth over the forecast period.
Contraceptive Pills Market Competitor Analysis
The contraceptive pills market is moderately consolidated in nature due to the presence of a few companies operating globally and regionally. The competition in the market is set to intensify as several key players are focusing on the expansion of their product portfolios through acquisitions and collaborations. The contraceptive pills market is expected to open up several opportunities for the new players, as well as the currently established market leaders. The key players in the market include Bayer AG, Amneal Pharmaceuticals LLC, Pfizer Inc., Mayne Pharma, and Teva Pharmaceuticals, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Rate of Unintended Pregnancies
4.2.2 Growing Awareness about Contraceptive Pills and Ease of Use and Low Cost
4.3 Market Restraints
4.3.1 Side Effects Associated with the Use of Contraceptive Drugs
4.3.2 Increased Usage of Alternative Birth Control Methods
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value- USD million)
5.1 By Hormone Type
5.1.1 Progestin Pills
5.1.2 Combination Pills
5.1.2.1 Monophasic
5.1.2.2 Triphasic
5.1.2.3 Other Combination Pills
5.2 By Category
5.2.1 Generic
5.2.2 Branded
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Amneal Pharmaceuticals LLC
6.1.3 Teva Pharmaceuticals
6.1.4 Abbvie Inc. (Allergan PLC)
6.1.5 Pfizer Inc.
6.1.6 Johnson & Johnson
6.1.7 Aurobindo Pharma Limited
6.1.8 Organon International (Merck & Co. Inc.)
6.1.9 Sanofi SA
6.1.10 Mayne Pharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS